Vaxxinova Aqua Business unit announces Technical and Commercial Director for Vaxxinova Chile
Bergen, Norway – April 1, 2022 – The Business Unit Aqua from Vaxxinova announces that starting April 1, 2022, Dr. med. vet Sandra Arcos Peña will be the Technical and Commercial Director for Vaxxinova Chile. Sandra will report to the BU Aqua Manager (Matias del Campo) and will be responsible for the LATAM cold-water aquaculture business, with special focus in the Chilean Salmon Industry.
Sandra is a Veterinarian Dr. from Universidad Austral de Chile, Aquaculture Engineer from Universidad Católica de Temuco, holds a Masters in Aquaculture at Universidad Santo Tomas, a Master on Salmonid Health at Universidad San Sebastian and an MBA at Universidad Austral de Chile. With 20 years of experience in development, technical support, and sales of pharmaceutical and biologicals for the Aquaculture industry in Chile. Sandra has held technical and commercial management positions in both Chilean and international health and pharma companies, among others as Technical Assistant in Recalcine (1999-2002) and later as Technical Assistant evolving into her last position Aquaculture Business Manager for Virbac Centrovet in Chile (since 2003).
BU Aqua of Vaxxinova is dedicated to provide solutions for the major challenges on the Norwegian market but has extended its scope of activity to provide effective biological preventive solutions to the Aquaculture industry in Chile. The team in Chile will be fully focused on the strategic R&D pipeline that started in 2017. This work targets novel vaccine products for prevention of major existing and emerging disease challenges in the Chilean Salmon Industry with registered and autogenous products, to be produced in dedicated Autogenous and GMP-standard factories in Germany and Italy.
Vaxxinova Norway and Vaxxinova Chile belong to Vaxxinova International, which is part of the family-owned EW Group. The Vaxxinova group is committed to disease prevention in livestock and aquatic animals and aims at providing a complete set of autogenous and licensed vaccines and diagnostic services based on long term partnerships with veterinarians and animal health professionals. Though Vaxxinova was officially named and founded in 2010, its predecessors have been in the livestock vaccine and diagnostics business since the 1950s, relying on more than 6 decades of expertise in disease prevention on production animals including poultry, fish, cattle and swine. Vaxxinova is supported by a global network, which comprises production, research & development, sales, and diagnostic facilities in 10 countries including Brazil, Chile, Germany, Italy, Japan, Jordan, Norway, the Netherlands, Thailand and the USA. The Vaxxinova products and services are available in more than 60 countries.
The EW Group specializes in animal genetics, animal nutrition and animal health, operates in over 100 countries and records consistent international growth. Its positive outlook and global orientation have led to an independent and significantly stable position in the market and a steady expansion